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Abstract
Background: Adherence of Streptococcus pneumoniae bacteria to lung cells is a first step in the
progression from asymptomatic carriage to pneumonia. Adherence abilities vary widely among S.
pneumoniae patient isolates. In this study, the binding properties of S. pneumoniae isolates and the
effects of binding on activation of the Nuclear Factor-Kappa-B (NFκB) pathway and cytokine
secretion by type II pneumocytes were measured.
Methods: Mechanisms of high- and low-binding S. pneumoniae adherence to A549 cells were
investigated by blocking putative receptors on bacteria and host cells with antibody and by eluting
choline-binding proteins off of bacterial surfaces. NFκB activation was measured by western blot
and immunocytochemistry and cytokine secretion was detected by a protein array.
Results: This study shows that S. pneumoniae isolates from pneumonia patients (n = 298) can vary
by as much as 1000-fold in their ability to bind to human lung epithelial cells. This difference resulted
in differential activation of the NFκB pathway. High-, but not low-binding S. pneumoniae used
Choline-binding protein A (CbpA) to bind to complement component C3 on epithelial cell
surfaces. Interleukin-8 (IL-8) was the only cytokine secreted by cells treated with either low- or
high-binding S. pneumoniae.
Conclusion: These results indicate that S. pneumoniae clinical isolates are not homogeneous in
their interaction with host epithelial cells. The differential activation of host cells by high- and low-
binding S. pneumoniae strains could have implications for the treatment of pneumococcal
pneumonia and for vaccine development.
Background
Streptococcus pneumoniae is a leading cause of community-
acquired pneumonia [1,2]. Yet S. pneumoniae can live
harmlessly in the upper respiratory tract of human hosts,
and be cultured from the nasopharynx from as many as
40% of the healthy adult population [3,4].
The pathogenicity of S. pneumoniae in pneumonia has
been the subject of much research [5-9]. Pneumonia
caused by S. pneumoniae begins when the bacteria move
from the upper respiratory tract to the lungs [10].
Although S. pneumoniae cannot adhere to healthy ciliated
upper respiratory epithelium [11], the bacteria do bind to
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bacteria through the lung during the first hours of acute S.
pneumoniae pneumonia is followed by red hepatization,
as the lung becomes engorged with blood. Cytokines
recruit neutrophils to the site of infection [14]. It is during
this stage that the S. pneumoniae pneumonia patient is
most at risk for severe consequences [15].
The adherence of S. pneumoniae to lung epithelial cells is a
critical first step in the progression from the asympto-
matic carrier state to pneumonia [16]. While studies have
indicated that S. pneumoniae can use host cell platelet-acti-
vating factor receptor (PAFr) as an anchor for adherence
[17-19], PAFr is not the sole binding site on human epi-
thelium used by S. pneumoniae. S. pneumoniae expresses a
75-kDa surface protein, Choline-binding protein A
(CbpA) which has been shown to bind to host cells via
secreted complement component C3 [20-22]. The bind-
ing of C3 on host cells can activate those cells and trigger
cytokine release, notably release of the neutrophil-recruit-
ing interleukin-8 (IL-8) [20,23]. Type II pneumocytes
have long been known to synthesize and secrete comple-
ment component C3 [24], providing a target for S. pneu-
moniae adherence to those cells via CbpA.
It has been noted that 75% of S. pneumoniae strains pos-
sess genes for CbpA [25] and thus have the potential to
bind to C3. This study shows that clinical isolates vary
widely in their ability to adhere to lung epithelial cells. A
survey of 298 patient isolates from the University of Kan-
sas Medical Center between 1996 and 2001 showed that
S. pneumoniae strains vary as much as 1000-fold in their
ability to bind to a human type II pneumocyte cell line
(Robson et al. poster B316, presented at 105th American
Society for Microbiology conference, Atlanta, GA, June
2005). Further, high-binding S. pneumoniae were selected
from a low-binding parent strain, producing two geneti-
cally-similar strains that vary in adherence by 2–3 log10.
The S. pneumoniae high binders selected from low-binder
parent strains have the same pulsed-field gel electrophore-
sis patterns and serotypes as their low-binding precursors
(Robson et al. poster B75, presented at 102nd American
Society for Microbiology conference, Salt Lake City, UT,
May 2002)
In this study, the binding properties of naturally-occurring
and artificially-evolved high- and low-binding S. pneumo-
niae isolates are compared and the effects of binding on
activation of the Nuclear Factor-Kappa-B (NFκB) pathway
and Interleukin-8 (IL-8) secretion by type II pneumocytes
are measured. Other studies have examined the impact of
pneumococcal adherence on the activation of lung epithe-
lial cells; however this is the first to evaluate a substantial
number of patient isolates for binding activity, and the
first to examine differences between high- and low-bind-
ing S. pneumoniae in the activation of lung epithelial cells.
Methods
Cell culture
A549, a human pneumocyte II cell line, was obtained
from ViroMed. Commercially prepared shell vials, con-
taining A549 on glass coverslips, were used for immuno-
cytochemistry. Cells used in other applications were
transferred and grown to confluence on sterile culture
dishes (Midsci) in commercially-prepared Dulbecco's
Modified Eagle's Medium (DMEM) (Sigma) with 10%
fetal bovine serum (Atlanta Biologicals) and 1% L-
glutamine/penicillin-streptomycin, 1% amphotericin B
and 1% MEM essential vitamin mix (Sigma). Cells were
transferred to 24-well plates for adherence assays or poly-
styrene culture dishes for Western blot samples. Cells
from passages 4 through 7 were used in all applications.
Identity of S. pneumoniae strains
S. pneumoniae isolates were collected from patients at the
University of Kansas Medical Center from 1996–2001. All
S. pneumoniae isolates in this study were from blood or
respiratory specimens of hospitalized patients with pneu-
monia. Medical records were retrospectively reviewed for
signs and symptoms of pneumonia. Pneumonia was
defined as the presence of a new pulmonary infiltrate by
chest radiograph, confirmed by a radiologist as compati-
ble with pneumonia.
Additionally the patient must have had at least two signs
or symptoms consistent with a lower respiratory tract
infection: temperature of 38°C or greater, new onset or
increased cough, purulent sputum, crackles, or dyspnea.
Isolates from patients with other diagnoses were not
included in this study. The Human Subjects Committee at
the University of Kansas Medical Center approved the
study protocol and the information was recorded in a
manner that preserved patient confidentiality. These pro-
cedures are in accordance with the guidelines for human
experimentation of the U.S. Department of Health and
Human Services.
Naturally-occurring high- and low-binders were chosen
from these patient isolates for further experiments.
Evolved high-binding S. pneumoniae were descendants of
low-binding strains: two patient isolates, serotypes 3 and
18C, and ATCC 6301, serotype 1. The reference strain
ATCC 6301 was obtained from the American Type Culture
Collection.
All S. pneumoniae used except for ATCC 6301 had different
genetic backgrounds, as determined by pulsed-field gel
electrophoresis using established techniques [26]. Artifi-
cially-evolved high-binding strains had the same PFGEPage 2 of 11
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ent strains.
Adherence assay and selection for adherence
24-well plates containing 200,000 A549 cells per well
were washed three times with Muller-Hinton broth
(MHB) (Remel) at room temperature. After washing, each
well was inoculated with 107 bacteria in 1 mL additive-
free DMEM, and incubated at 37°C, 5% CO2 for two
hours. The cells were then washed three times with room
temperature MHB, and cells were lysed with 0.02%
trypsin (Sigma) for 30 minutes. Bacterial viability was not
affected by 0.02% trypsin. The A549 cell lysate was then
diluted and plated on sheep blood agar (SBA) (Remel),
using a standard spread plate technique. Colony counts
from the cell lysate dilutions determined the number of
adherent bacteria per 100 A549 cells.
The evolved high binding strains of S. pneumoniae were
derived from low binding parent strains by using sequen-
tial passage on fresh A549 monolayers. When selecting for
adherence, the adherent bacteria from the previous pas-
sage on A549 cells were used to inoculate new cell layers
of A549 for subsequent passages.
In choline-elution experiments, bacteria were soaked in
sterile 2% choline (Sigma) in saline for 20 minutes, cen-
trifuged and resuspended in sterile saline before adding
the bacteria to A549 cells in 24-well plates.
In all adherence experiments, A549 viability immediately
prior to the final treatment with 0.02% trypsin was over
90%, as determined by trypan blue exclusion.
Blocking of receptors on S. pneumoniae and A549
The CbpA proteins on S. pneumoniae were blocked by
soaking bacteria in sterile saline supplemented with
either1:100 rabbit anti-CbpA, or 1:100 normal rabbit
serum as the negative control, for 30 minutes at room
temperature with gentle shaking. The bacteria were then
washed in sterile saline prior to being added to A549 cells
to assess adherence.
To block the C3 and PAF-receptor on the A549 cells, the
epithelial cells were treated with 1:100 rabbit anti-human
C3 antibody, 1:100 goat anti-human PAFr antibody
(Santa Cruz Biotechnology), or 1:100 normal rabbit
serum as the negative control for 2 hours. The cells were
then washed with MHB and inoculated with a standard
suspension of bacteria.
Serotyping
Serotyping was performed using bead agglutination, as
previously described [27].
Western blot for IκB
Protein preparations from A549 cells treated with high-
and low-binding bacterial strains (MOI = 50 bacteria/cell)
were quantified using a protein quantification kit (Bio-
Rad). 50 µg of protein was electrophoresed in a 30% poly-
acrylamide gel, transferred to a polyvinylidine fluoride
(PVDF) membrane (BioRad), Ponceau stained, blocked in
5% nonfat dry milk (NFDM) in Tris-buffered saline-
Tween (TBST), and probed with rabbit anti-human IκB
(Santa Cruz Biotechnology) in 5% NFDM-TBST, with
horseradish-peroxidase (HRP) conjugated donkey anti-
rabbit IgG (Santa Cruz Biotechnology) used as a second-
ary antibody. IκB bands were visualized using ECL sub-
strate (Amersham Biosciences) and autoradiography.
Computerized densitometry was used to analyze changes
in IκB band density relative to negative controls. Mem-
branes were stripped and reprobed with mouse anti-
human actin antibody to confirm that equivalent
amounts of total protein had been loaded into each well.
Western blot for eluted CbpA
Choline-binding proteins were eluted from S. pneumoniae
as described above. Supernatants were collected and ster-
ile-filtered and proteins were precipitated using a standard
tricholoracetic acid technique. The proteins were electro-
phoresed on a 30% polyacrylamide gel and transferred to
PVDF as described above. Membranes were Ponceau
stained, blocked in 5% NFDM-TBST, and probed with
1:100 rabbit anti-CbpA (kindly provided by Drs. Elaine
Tuomanen and Margaret Hostetter). HRP-conjugated
donkey anti-rabbit IgG was used as a secondary antibody.
Immunocytochemistry
A549 cells grown on glass coverslips in shell vials
(ViroMed) were used for immunocytochemistry. Cell lay-
ers were washed with MHB and inoculated with 107 bac-
teria per vial, as in adherence assays. At the end of the
incubation period (4, 6, or 8 hours at 37°C, 5% CO2), cell
layers were washed three times with ice-cold phosphate-
buffered saline (PBS) and fixed overnight at 4°C in 5%
formalin in PBS. Immunocytochemistry was conducted
using a kit (BioGenex) with 1:25 rabbit anti-NFκB (Santa
Cruz Biotechnology) used as a primary antibody. Slides
were examined at 400 x.
Cytokine array
Supernatants from A549 cells treated with high and low
binding S. pneumoniae isolates were assayed for the pres-
ence of 42 human cytokines using a RayBio® Human
Cytokine Antibody Array III, following manufacturer's
instructions (Raybiotech). Cytokine array luminesence
was visualized with ECL substrate and autoradiography.Page 3 of 11
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IL-8 was measured from the supernatant of treated epithe-
lial cells using the Bio-plex suspension array system with
fluorescently dyed Luminex microspheres (BioRad). Cul-
ture supernatant was collected from cells at 30 minutes, 1
hour, 2 hours, 4 hours, 6 hours and 8 hours after inocula-
tion with bacteria. The culture supernatant was stored at -
70°C until tested. Assays were performed in a 96-well fil-
tration plate (Millipore) with 5,000 beads coated with
human IL-8 antibody. The standards, samples or blanks
were mixed with beads in a final volume of 100 µl and
incubated for 30 minutes at 25°C with continuous shak-
ing. After three washes, biotinylated antibodies were
added for 30 minutes. Beads were again washed three
times and streptavidin-phycoerythrin was added for 10
minutes. The fluorescence intensity of the beads was
measured using the Bio-Plex array reader. Bio-Plex Man-
ager software was used for data analysis. The level of IL-8
detection was 7.8 pg/ml. IL-8 standards were assayed in
triplicate with each assay; n = 7 samples run per treatment
per timepoint.
Statistical analysis
All statistical analysis was done in Statistical Analysis Soft-
ware (SAS). Graphs were made using Microsoft Excel.
Pulsed-field gel electrophoresis
Genomic DNA from artificially-evolved and naturally
occurring S. pneumoniae strains was prepared as previously
described [26]. The fragments were resolved using a Gene-
Path System (BioRad) set on the "Enterococcus" running
program.
Results
S. pneumoniae clinical isolates vary in ability to bind to 
epithelial cells
Clinical isolates of S. pneumoniae (n = 298) were assayed
for ability to bind to A549 cells, a human type II pneumo-
cyte cell line. Bacterial isolates varied by more than 1000-
fold in their ability to adhere to cells. Table 1 summarizes
S. pneumoniae clinical isolates' adherence abilities into 4
distinct categories: low, low-moderate, moderate and
high. The majority (66%) of S. pneumoniae assayed were
low binders, adhering to lung cells at an average rate of
0.82 ± 0.52 bacteria per 100 A549 cells. A small minority
(2%) of S. pneumoniae were high binders, adhering to lung
cells with an average rate of 2,360 ± 770 bacteria bound
per 100 cells. The remainder of the isolates were low-
moderate or moderate binders. Differences in adherence
ability among the four categories was statistically signifi-
cant (one-way ANOVA p-value << 0.005; F = 167.84
where Fcritical = 2.74) and reproducible. Neither serotype
nor binding ability predicted for invasive disease, defined
here as the isolate having been cultured from blood
(Cochran-Mantel-Haenszel test, p = 0.41 and p = 0.82,
respectively). No relationships were observed between
serotype and binding ability, or between antibiotic resist-
ance and binding ability of S. pneumoniae.
High-binding S. pneumoniae isolates use CbpA to bind to 
C3 on epithelial cell surfaces
To investigate pneumocyte receptors used by high- and
low-binding S. pneumoniae, PAFr and C3 on the A549 cells
were blocked with specific antibodies. Pre-treating A549
cells with anti-PAFr antibody did not reduce adherence of
high-binding S. pneumoniae strains (data not shown).
However, adherence of low-binding S. pneumoniae strains
to A549 cells was slightly reduced (40%) by blocking PAFr
on host cells with antibody (data not shown).
Blocking cell surface-bound complement component C3
with anti-human C3 antibody significantly reduced
adherence of all but one high binding S. pneumoniae strain
(Figure 1A). Alternatively, only one low-binding S. pneu-
moniae strain bound less avidly to A549 cells treated with
anti-C3 antibody than to control cells (Figure 1B).
Since choline-binding proteins (Cbps) on bacteria have
been implicated in S. pneumoniae adherence to host cells,
their involvement in the differential adherence of S. pneu-
moniae strains was investigated. All Cbps were eluted off
of the surfaces of high- and low-binding S. pneumoniae
using standard methodology [28]. Elution of choline-
binding proteins from S. pneumoniae surfaces eliminated
bacterial adherence to A549 cells, among both high-bind-
ing and low-binding strains. Thus, choline-binding pro-
teins are necessary for adherence of both high- and low-
binding S. pneumoniae to epithelial cell surfaces.
Table 1: Observed adherence properties of naturally-occurring S. pneumoniae clinical isolates
Binding category % of total clinical isolates observed (n = 
298)
Average S. pneumoniae bound per 100 
A549 cells ± standard deviationa
low 66% (n = 194) 0.82 ± 0.52
low-moderate 19% (n = 56) 5.2 ± 1.8
moderate 14% (n = 42) 30.7 ± 11.2
high 2% (n = 6) 2360 ± 770
a MOI = 50 bacteria/cellPage 4 of 11
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Adherence of high-binders, but not low-binders, is reduced by blocking CbpA or C3Figur  1
Adherence of high-binders, but not low-binders, is reduced by blocking CbpA or C3. Solid bars, negative control; open bars, 
bacteria pre-treated with anti-CbpA antibody; dotted bars, A549 cells pre-treated with anti-C3 antibody. Negative control 
A549 cells pre-treated with normal rabbit serum. All values are mean ± one standard deviation, based on three independent 
experiments. Mean values are above each bar. The Y-axis units differ on graphs 1A and 1B. 1A. High-binding S. pneumoniae are 
identified by serotype along X-axis. 6301 evolved, 3 evolved, and 18C evolved are high-binding descendants of low-binding par-
ent strains. Isolates identifed as 6 B all share that serotype but have different PFGE patterns. 1B. Low-binding S. pneumoniae 
strains are identified by serotype along X-axis. 6301 parent, 3 parent, and 18C parent are initial low-binding strains of 6301 
evolved, 3 evolved, and 18C evolved.
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niae adherence to A549 cells, bacteria were treated with
anti-CbpA (provided by Drs. Hostetter and Tuomanen).
Similar to blocking host cell C3 with anti-C3 antibody,
blocking pneumococcal CbpA with anti-CbpA antibody
significantly reduced adherence of all but one high-bind-
ing S. pneumoniae strain to A549 cells (Figure 1A). Block-
ing CbpA on low-binding S. pneumoniae with antibody
did not significantly reduce adherence to A549 cells (Fig-
ure 1B).
The removal of CbpA from bacterial surfaces by elution in
2% choline solution was confirmed by Western blot.
Membranes were probed with anti-CbpA. Eluents from all
high-binding and all but one low-binding S. pneumoniae
strains exhibited CbpA-positive bands at 75 kDa. These
data indicate that all but one isolate used in these experi-
ments express CbpA, and that this protein was success-
fully removed from bacterial surfaces by choline elution
(data not shown).
High-binding S. pneumoniae activate NFκB pathway
Activation of the NFκB pathway in A549 was detected by
the degradation of the NFκB inhibitor, IκB. Figure 2
shows Western blots for IκB from A549 cells treated with
high- and low-binding S. pneumoniae strains at different
time points. Both high- and low-binding S. pneumoniae
induced IκB degradation in A549 cells. However, at the 4,
6 and 8 hour time points, IκB levels were significantly
lower among all cells treated with high-binding S. pneu-
moniae compared to all cells treated with low-binding
strains (two-way ANOVA comparison of IκB band densi-
ties for cells treated with high and low binders at 4, 6, and
8 hours relative to zero timepoint). Table 2 summarizes
statistical analysis of IκB degradation in A549 after expo-
sure to high-and low-binding S. pneumoniae strains. Figure
2A shows IκB loss induced by an artifically-evolved high-
binder and its genetically-similar low-binding parent
strain. Figure 2B shows IκB loss induced by two unrelated
high- and low-binder clinical strains. Binding of C3 on
A549 surfaces by anti-C3 antibody did not induce IκB
degradation.
Immunocytochemistry confirmed the activation of NFκB
pathway by demonstrating the migration of NFκB from
the cytoplasm into the nucleus in A549 cells treated with
high-binding, but not low binding, strains (Figure 3).
Cytokine activation by high and low binding S. 
pneumoniae
Cytokine release was evaluated using a protein array that
included 42 cytokines. Culture fluid from A549 cells inoc-
ulated with high- and low-binding S. pneumoniae was
tested after 2 hours of incubation. The only cytokine
detected after exposure to either high- or low-binding
strains was IL-8 (Figure 4). To determine whether high- or
low-binding S. pneumoniae induced different amounts of
IL-8 secretion from A549 cells, a Luminex bead system
was used. No significant difference in IL-8 concentrations
was observed in the supernatants of cells treated with
high- versus low-binders at any time point prior to 8
hours. Cells treated with low-binders released signifi-
cantly more IL-8 at 8 hours than did those treated with
high-binders (Wilcoxon Rank-Sum, two-tailed p-value <
0.05). Negative controls induced only negligible IL-8
secretion, near the detection limit of the system (1.6 pg/
mL). Measurement of other cytokines, TNF-α and IL-4,
was below the detection limit of the system at all time
points for all cells.
Discussion
Adherence to host cells is the first step in the progression
from S. pneumoniae carriage to disease [3]. While adher-
ence to host cells by S. pneumoniae has been shown in a
number of studies [10,12,17,20-22,29,30], this is the first
investigation to compare adherence across a large sample
of S. pneumoniae isolates from pneumonia patients. An
important conclusion of this study is that S. pneumoniae
Table 2: Percentage of IκB remaining in A549 after addition of high- and low-binding S. pneumoniaea
Time after addition of bacteria
Treatment of A549 cellsb 0 hours 4 hours 6 hours 8 hours
low binders 100% 81.3% 65.6% 62.1%
high binders 100% 60.8% 34.9% 25.1%
ANOVA p-valuec 0.423 2.3 × 10-7 1.3 × 10-7 1.1 × 10-8
a Combined average of IκB levels from cells treated with 7 low-binders or 7 high-binders. Each S. pneumoniae isolate was tested in triplicate thus 
each measurement is the average from 21 different experiments at each time point.
b A549 cells were incubated with an MOI of 50 bacteria/cell for the listed time periods. Proteins from the cell culture were then harvested for the 
analysis of IκB degradation.
c Two-way analysis of variance comparing IκB degradation in A549 treated with low binders and high binders for each time period. IκB degradation 
measured as described in materials and methods.Page 6 of 11
(page number not for citation purposes)
BMC Infectious Diseases 2006, 6:71 http://www.biomedcentral.com/1471-2334/6/71
Page 7 of 11
(page number not for citation purposes)
High-binders induce prolonged degradation of IκB compared to low-bindersFi ure 2
High-binders induce prolonged degradation of IκB compared to low-binders. All values are mean ± one standard deviation, 
based on three independent experiments. 2A. IκB degradation induced by serotype 3 evolved high-binder and 3 low-binding 
parent strains. Closed squares, IκB level relative to time zero in A549 treated with low-binder. Open triangles, IκB level rela-
tive to time zero in A549 treated with high-binder. Representative Western blots for IκB are shown below each line graph. 
2B. IκB degradation induced by serotype 9N low-binding clinical isolate and serotype 6B high-binding clinical isolate. Closed 
squares, IκB level relative to time zero in A549 treated with low-binder. Open triangles, IκB level relative to time zero in A549 
treated with high-binder. Representative Western blots for IκB shown below line graph.
BMC Infectious Diseases 2006, 6:71 http://www.biomedcentral.com/1471-2334/6/71isolates' ability to adhere to lung cells vary by more than
1,000-fold. Additionally, S. pneumoniae with higher bind-
ing activity to host cells have a prolonged activation of the
NFκB pathway.
Patients infected with high-binding isolates could be at
increased risk compared to patients infected with the
more common low-binding isolates. While high-binding
S. pneumoniae strains are relatively uncommon among
patient isolates, they could still be important clinically.
The United States' Centers for Disease Control expects at
least 100,000 cases of pneumococcal pneumonia every
year in the United States alone [31]. Thus, 2,000 of those
patients would be expected to be infected with high-bind-
ing strains if the percentages reported here are representa-
tive of S. pneumoniae isolates overall. Although this
investigation does not compare outcomes of patients
infected with high- and low-binding S. pneumoniae, stud-
ies are in progress to evaluate this association. These stud-
ies require the evaluation of more patients since high-
binding bacteria comprise such a small minority (2%) of
patient isolates.
There was no correlation between isolate ability to bind to
host cells and serotype, although other studies have
shown a relationship between pathogenicity and serotype
[32] and invasiveness and serotype [33]. In this study, 18
serotypes were found among 298 patient isolates. While 3
of 6 high-binding isolates were serotype 6B, this capsular
type was not statistically linked to increased adherence,
since 6B is a common serotype in this sample (n = 39;
13%).
High-binding S. pneumoniae used a bacterial surface pro-
tein, CbpA, to bind to C3 on lung epithelial cells, while
low-binding strains did not use CbpA or C3. This interac-
tion between CbpA and C3 has been noted by others
[21,22]. CbpA is also capable of binding to other cellular
receptors, such as the polymericimmuno globulin recep-
tor (pIgR) on nasopharyngeal epithelial cells [30,34] and
PAFr [17,29]. In this study blocking host PAFr did not
reduce the adherence of high-binders to A549 cells.
Orihuela et al. observed that CbpA is required for
nasopharyngeal colonization, progression from the
nasopharynx to the lower respiratory tract, and the pro-
gression from bacteremia to meningitis in a mouse model
but is not needed for S. pneumoniae survival in murine
lungs or blood [35]. In contrast, Paton and Berry showed
that CbpA does not contribute to S. pneumoniae patho-
genicity in mice infected via intraperitoneal injection [36].
Future studies are needed to elucidate the importance of
CbpA on virulence in humans infected with S. pneumo-
niae.
NFκB migrates to the nucleus after cell interaction with high-binders, but not low-binders, 4 hours after inoculation with act iaFigure 3
NFκB migrates to the nucleus after cell interaction with high-
binders, but not low-binders, 4 hours after inoculation with 
bacteria. NFκB is detected as a dark brown stain against a 
pale lavender background. 3A, negative control. 3B, A549 
incubated with serotype 3 low-binders (Black arrow shows 
NFκB protein in the cytoplasm). 3C, A549 incubated with 
serotype 3 high-binders (White arrow shows NFκB protein 
detected in the nucleus).Page 8 of 11
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strains have a transparent colony morphology, while col-
onies of low-binding S. pneumoniae are likely to be
opaque [12,37] Further, it has been observed that trans-
parent S. pneumoniae strains contain more CbpA than do
opaque strains [21] and that individual S. pneumoniae iso-
lates can fluctuate between highly-adherent transparent
and less-adherent opaque phases [37,38]. Phase variation
was not noted when comparing high-binding S. pneumo-
niae isolates with low-binding S. pneumoniae isolates. All
clinical strains used exhibited stable binding activity and
colony morphology over at least 4 years and after numer-
ous passages from the freezer to agar. Additionally, artifi-
cially-evolved high binders had the same colony
morphology as did their low-binding progenitors. Thus,
in this instance it does not seem that colony morphology
was responsible for differences in binding ability of these
clinical isolates. It is possible that certain colony morpho-
types were selected out in the host or during the infectious
process. Those studies would require additional patient
isolates and extensive review of patient history. Interest-
ingly, four of the high-binding S. pneumoniae isolates
came from patients under the age of 5 years. This observa-
tion could imply that high-binding S. pneumoniae using
CbpA are more prevalent in children than in adults. This
interesting finding requires further study.
CbpA has been considered as a vaccine candidate. CbpA is
immunogenic in rabbits and S. pneumoniae human volun-
teers [39,40]. Recently, Zhang et al. found that children
with higher serum levels of anti-CbpA antibodies had a
reduced risk of S. pneumoniae carriage [41]. Thus, CbpA-
mediated binding to host cells could be an important con-
tributor to S. pneumoniae pathogenicity and could have
implications for the development of vaccines directed
against CbpA.
In this study, high-binding S. pneumoniae were observed
to strongly activate the NFκB pathway in lung epithelial
cells. NFκB activation was independent of serotype and
genetic background. Although NFκB activation often
leads to secretion of many different cytokines, in this
study only IL-8 was released by cells treated with either
high- or low-binding S. pneumoniae. Epithelial cells sur-
prisingly produced more IL-8 after 8 hours of incubation
with low binding S. pneumoniae than with high binding
isolates. This indicates differences in intracellular path-
ways within the epithelial cells after activation of different
receptors by S. pneumoniae. Additionally, the interaction
and recruitment of other cell types to the site of infection
may be effected by this differential activation. A study by
Jones et al. showed that IL-1 and TNF-α were rapidly
released by murine lungs in response to S. pneumoniae
infection [42]. Thus, although the results from the current
study indicate a difference in the initial interaction of S.
pneumoniae with host epithelial cells alone, further inves-
tigation in the presence of other cell types is needed to
understand the implications of this difference in epithe-
lial cell activation.
NFκB activation and IL-8 secretion by pneumocytes
recruit neutrophils to the lung [43,44]. While neutrophils
kill bacteria, they also damage lung tissue [44]. It is not
clear whether the increased IL-8 secretion in pneumocytes
treated with low-binding S. pneumoniae is ultimately pro-
tective or destructive. It is also unclear why the increased
NFκB activation seen in cells treated with high-binding S.
pneumoniae did not result in increased IL-8 secretion.
Conclusion
This study has shown that S. pneumoniae isolates have dif-
ferences in ability to bind to human lung epithelial cells.
This difference was reproducible and resulted in differen-
Supernatants from A549 cells treated with high- and low-binding S. pneumoniae wer  evalu  it  a RayBio® Human Cytokine A tib dy Array III, which detects 42 different h ma  cytokinesFigu e 4
Supernatants from A549 cells treated with high- and low-
binding S. pneumoniae were evaluated with a RayBio® Human 
Cytokine Antibody Array III, which detects 42 different 
human cytokines. 1A and 2A, positive control; 3A and 4A, 
negative control; 5A, ENA-78; 6A, GCSF; 7A, GM-CSF, 8A, 
GRO; 9A, Gro-α; 10A, I-309; 11A, IL-1α; 12A, IL-1β; 1B, IL-
2; 2B, IL-3; 3B, IL-4; 4B, IL-5; 5B, IL-6; 6B, IL-7; 7B, IL-8; 8B, 
IL-10; 9B, IL-12; 10B, IL-13; 11B, IL-15; 12B, IFN-γ; 1C, MCP-
1; 2C, MCP-2; 3C, MCP-3; 4C, MCSF; 5C, MDC; 6C, MIG; 
7C, MIP-1; 8C, RANTES; 9C, SCF; 10C, SDF-1; 11C, TARC; 
12C, TGF-β; 1D, TNF-α; 2D, TNF-β; 3D, EGF; 4D, IGF-1; 
5D, angiogenin; 6D, oncostatin M; 7D, thrombopoietin; 8D, 
VEGF; 9D, PDGF; 10D, leptin; 11D, negative control; 12D, 
positive control. The positive result for IL-8, in position 7B, 
with negative results for all other cytokines, was observed 
for A549 cells treated with both high- and low-binding bacte-
ria. Experiment replicated with four different high-binding, 
and four different low-binding, S. pneumoniae strains.Page 9 of 11
(page number not for citation purposes)
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High binding S. pneumoniae adhered via an interaction
between CbpA and C3. These results indicate that S. pneu-
moniae are not homogeneous in their interaction with
host epithelial cells and may have differences in patho-
genicity. Further studies are needed to elucidate the path-
ogenic implication of this difference in binding and
activation of epithelial cells.
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